Sciullo, P. D., Menay, F., Cocozza, F., Gravisaco, M. J., Waldner, C. I., & Mongini, C. (2019). Systemic administration of imiquimod as an adjuvant improves immunogenicity of a tumor-lysate vaccine inducing the rejection of a highly aggressive T-cell lymphoma. Clinical immunology (Orlando, Fla.), 203, 154. https://doi.org/10.1016/j.clim.2019.04.013
Style de citation ChicagoSciullo, Paula Di, Florencia Menay, Federico Cocozza, María José Gravisaco, Claudia I. Waldner, et Claudia Mongini. "Systemic Administration of Imiquimod as an Adjuvant Improves Immunogenicity of a Tumor-lysate Vaccine Inducing the Rejection of a Highly Aggressive T-cell Lymphoma." Clinical Immunology (Orlando, Fla.) 203 (2019): 154. https://dx.doi.org/10.1016/j.clim.2019.04.013.
Style de citation MLASciullo, Paula Di, et al. "Systemic Administration of Imiquimod as an Adjuvant Improves Immunogenicity of a Tumor-lysate Vaccine Inducing the Rejection of a Highly Aggressive T-cell Lymphoma." Clinical Immunology (Orlando, Fla.), vol. 203, 2019, p. 154.